Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 6/20 | 0.54 |
| ▸ | BCHE | P06276 | 6/20 | 0.54 |
| ▸ | BACE1 | P56817 | 5/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.51 |
| ▸ | CCR2 | P41597 | 1/20 | 0.51 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.51 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.49 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.48 |
| ▸ | SCN1A | P35498 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1774196 | 1.00 | ACHE (0.54) | ACHEBCHEBACE1OPRK1MEN1 | |
| SCHEMBL1775084 | 0.81 | HRH4 (0.69) | ACHEBCHEBACE1OPRK1ROCK2 | |
| SCHEMBL1773531 | 0.81 | HRH4 (0.69) | ACHEBCHEBACE1OPRK1ROCK2 | |
| SCHEMBL13326542 | 0.81 | DRD2 (0.65) | ACHEBCHEBACE1OPRK1ROCK2 | |
| SCHEMBL4868726 | 0.79 | ROCK2 (0.56) | ACHEBCHEBACE1OPRK1ROCK2 | |
| SCHEMBL7828368 | 0.78 | NOS3 (0.58) | ACHEBCHEBACE1MEN1KMT2A | |
| SCHEMBL331017 | 0.77 | BCHE (0.68) | ACHEBCHEBACE1OPRK1KMT2A | |
| SCHEMBL331018 | 0.77 | BCHE (0.68) | ACHEBCHEBACE1OPRK1KMT2A | |
| SCHEMBL3911653 | 0.76 | CCNK (0.61) | ACHEBCHEBACE1ROCK2 | |
| SCHEMBL3911658 | 0.76 | CCNK (0.61) | ACHEBCHEBACE1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966162-B1 | PYRIMIDINE DERIVATIVES | ZIARCO PHARMA LTD (GB) | 2017-03-15 | — | — | EP | disclosed |
| US-7943628-B2 | Pyrimidine derivatives | PFIZER LIMITED (GB) | 2011-05-17 | — | — | US | disclosed |
| US-20070185075-A1 | Pyrimidine derivatives | PFIZER LIMITED | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185075-A1 | Pyrimidine derivatives | TYMS, DPYD, TYMP | ACHE 4243/4885BCHE 3238/4885BACE1 4179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.